That's one part of it.
The other part, in terms of looking for adverse events or problems, will actually come primarily from the large-scale studies. Again, because of the way they're constructed, the studies actually have research ethics boards that oversee them. They have data safety monitoring boards that look at it. Because they are clinical studies, they have a number of intrinsic checks and balances to allow us to collect that information in the best possible way. Once a thing is on the market, if it's not in a clinical trial or a formal monitoring system, then we rely on the mandatory reporting. Again, by regulation, the only groups that are mandated to report are the manufacturers.
The way we wanted to make sure we're getting the best information is to put conditions on the manufacturers to conduct these studies, and then have those studies, including all the data, submitted to Health Canada for review.